Studies such as EMPEROR-Preserved, EMPEROR-Reduced, and DELIVER have reported heart failure hospitalization rates of 13.8%, 19.4%, and 16.4%, respectively, in patients treated with SGLT2 inhibitors compared to placebo. This evidence concerns the gene SLC5A2 and heart failure.